| 2018-12-10 10:14:12|
BHVN 10:14 12/10 12/10/18
Biohaven's rimegepant 'definitively' safe, well tolerated, says Piper Jaffray
Biohaven Pharmaceutical this morning reported positive data from a 12-month safety study of 1,780 patients, which included regularly scheduled liver function tests, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The bottom line is that rimegepant now definitively appears to be a safe and well-tolerated treatment and that Biohaven has successfully engineered out the liver toxicity associated with the first generation oral calcitonin gene-related peptides, says the analyst. He adds rimegepant also demonstrated efficacy in prevention, which he thinks bodes well for the ongoing pivotal trial. Van Buren reiterates an Overweight rating on Biohaven Pharmaceutical with a $65 price target.